1. FINAL TRANSCRIPT CAH - Q2 2007 Cardinal Health, Inc.
Earnings Conference Call Event Date/Time: Jan. 25. 2007 / 11:00AM
ET www.streetevents.com Contact Us 2007 Thomson Financial.
Republished with permission. No part of this publication may be
reproduced or transmitted in any form or by any means without the
prior written consent of Thomson Financial.
2. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call CORPORATE
PARTICIPANTS Jason Strohm Cardinal Health, Inc. - VP, IR Kerry
Clark Cardinal Health, Inc. - President, CEO Jeff Henderson
Cardinal Health, Inc. - CFO Mark Parish Cardinal Health, Inc. -
CEO, Healthcare Supply Chain Services Dave Schlotterbeck Cardinal
Health, Inc. - CEO, Pharmaceutical, Medical Products CONFERENCE
CALL PARTICIPANTS Christopher McFadden Goldman Sachs - Analyst Tom
Gallucci Merrill Lynch - Analyst Glen Santangelo Credit Suisse -
Analyst Ross Muken Deutsche Bank - Analyst Larry Marsh Lehman
Brothers - Analyst Ricky Goldwasser UBS - Analyst Lisa Gill JP
Morgan - Analyst Sandy Draper JMP Securities - Analyst David Biel
Morgan Stanley - Analyst Steven Halper Thomas Weisel Partners -
Analyst Charles Bardy Citigroup - Analyst Robert Willoughby Banc of
America Securities - Analyst PRESENTATION Operator Good day, Ladies
and Gentlemen, and welcome to the Q2 2007 Cardinal Health
Incorporated earnings conference call. [OPERATOR INSTRUCTIONS] And
I would now like to turn the presentation over to your host for
today's call to Mr. Jason Strohm, Vice www.streetevents.com Contact
Us 1 2007 Thomson Financial. Republished with permission. No part
of this publication may be reproduced or transmitted in any form or
by any means without the prior written consent of Thomson
Financial.
3. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call President of
Investor Relations. Please proceed. Jason Strohm - Cardinal Health,
Inc. - VP, IR Thanks, Michelle. Good morning and welcome to
Cardinal Health's fiscal 2007 second quarter earnings conference
call. Our remarks today will be focused on the Company's
consolidated and business segments results for the quarter which
are included in a press release and attached financial tables. If
any of you have not received a copy of our earnings release or the
financial attachment you may access it over the Internet or at our
investor page at www.CardinalHealth.com. Additionally, there are a
handful of slides we will be reviewing which can also be found on
the website. Speaking on our call today will be Kerry Clark,
President and CEO; and Jeff Henderson, CFO. Also participating with
us today for Q&A are Mark Parish, CEO of Healthcare Supply
Chain Services and David Schlotterbeck, CEO of Pharmaceutical and
Medical Products. After our formal remarks we will open up the
phone lines for your questions. As always when we get to your
questions, we ask that you limit yourself to one. During the course
of this call we will make forward-looking statements. These
statements are subject to risks and uncertainties that could cause
actual results to differ materially from those projected. Please
see our press release and our other SEC filings for a full
discussion of the risk factors associated with them. In addition,
we will reference non-GAAP financial measures. A reconciliation of
GAAP to non-GAAP financial information is included at the end of
the slide presentation. At this time I'd like to turn the call over
to Kerry Clark, Cardinal Health's President and CEO. Kerry Clark -
Cardinal Health, Inc. - President, CEO Thanks, Jason. Welcome,
everybody and thanks for joining the call. It's been an exciting
week for us. Everyone has worked hard to reach the agreement we
announced this morning on the PTS sale agreement and of course
we're also pleased to announce strong Q2 results. Let me start with
a very brief recap of the PTS sale and then I'll provide you with
my thoughts on the quarter. As you saw in this mornings
announcement, we've reached an agreement to sell PTS to Blackstone
for $3.3 billion. This is a very good deal for Cardinal Health
shareholders and we're pleased with the rapid progress in reaching
this agreement. We continue to believe it was a good strategic
choice to divest PTS because it will allow us to better focus on
our core business and will lift our overall return on capital. And
as we've said, we intend to use the net proceeds to repurchase
shares. Turning to the quarter, I think we performed quite well.
Top line growth was solid in each segment, and we had double digit
operating earnings growth in all four segments. On a non-GAAP
basis, our operating margin expanded 8 basis points versus year
ago. Cardinal Health's margin remains the highest in our industry
reflecting our diversified portfolio. As you will recall, we are
measuring the performance of our supply chain businesses on the
basis of economic profit growth, which factors in the use of
capital and ensures we are operating in a disciplined fashion.
During the quarter, our healthcare Supply Chain services
pharmaceutical business expanded economic profit margin both year
on year and sequentially and we're making good progress to do the
same in our Supply Chain service medical business with strong
sequential growth. We're also making good progress on our journey
from a holding company to an integrated operating company. Q2 was
our first full quarter with our integrated One Cardinal Health
sales team fully deployed and calling on our hospital customers.
Through this organization, we expect to be able to better leverage
our Supply Chain capabilities from manufacturer to bedside to
create innovative customer solutions. For example, at the HIMMS
conference in late February, we'll be launching a new program that
integrates our Pharmaceutical Distribution Services with Pyxis,
Alaris, and Care Fusion products. We also continue to progress on
our Shared Services Organizations as evidenced by our second
straight quarter of good, core, SG&A control. We're on track
with our implementation schedules and headcount reductions.
www.streetevents.com Contact Us 2 2007 Thomson Financial.
Republished with permission. No part of this publication may be
reproduced or transmitted in any form or by any means without the
prior written consent of Thomson Financial.
4. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call This quarter, we
also reviewed the performance of Cardinal Health acquisitions over
the last three years to be sure the firms that we have acquired are
on track to deliver positive economic profit growth by year three.
We're happy to report that eight of nine are on track with Alaris
leading the way. Jeff will provide more detail about our
acquisition performance in his remarks. Looking ahead, we believe
our current portfolio is well positioned to grow over the medium
term by capitalizing on two key needs at the healthcare industry.
Productivity and patient safety. In the American College of
Healthcare Executives fifth annual poll, financial challenges,
personnel shortages, and patient safety were dominant themes. These
are challenges we can help solve through our Supply Chain Services
and our medical and clinical products. Despite continued pressures
on costs, we believe total healthcare spending will outpace
population growth, creating opportunities for companies like
Cardinal Health that have good value, market leading products, and
best-in-class cost structures and innovative customer offerings.
That said, I want to update you on three longer term initiatives
under way. We expect these initiatives to be future growth engines
for Cardinal Health. First, generics. We continue to experience
strong sales growth with favorable margins in the core distribution
of generics. Our PharMed acquisition which primarily sells generic
pharmaceuticals to retail pharmacies is performing above our
expectations. Going forward, we have undertaken an extensive
sourcing effort with both established and emerging suppliers to
further improve margins. The market is extremely competitive on the
supply side which creates a favorable buying environment which
allows us to deliver very compelling value to our customers. Next
is the Specialty Pharmaceutical market. In our news release this
morning, we announced plans to acquire Specialty Scripts Pharmacy,
a privately held Specialty Pharmaceutical Services Company. While
this acquisition is relatively small, it is strategic. Specialty
pharmacy is one of the fastest growing segments of the market and
is complementary to the specialized nature of our nuclear pharmacy
assets as well as our blood and plasma distribution business and
our third party logistics unit. Our goal is to provide a higher
level of service to Pharmaceutical manufacturers who are asking us
to develop this capability. And finally, international. Today,
about 2% of our revenue growth comes from the sale of products
outside the U.S. But as I've said before, this is a longer term
opportunity. In Q2, international revenue grew 12%, with balanced
growth between Canada and Western Europe. For perspective, we do no
pharmaceutical distribution internationally so these numbers are
quite good. We continue to develop a focused and disciplined
strategy and an organization structure to capture a larger portion
of the hospital supply opportunities in Canada, UK, Germany, and
France. Now, before turning over to Jeff, I'd like to step back and
summarize where I see Cardinal Health today. I believe we have
focused our portfolio and strategies to leverage Cardinal Health's
skills and capabilities. We are making progress in leveraging our
scale through One Cardinal Health initiatives. Our core business
segments are now performing better with potential for the future if
we continue to be customer focused and operate with discipline. At
the same time, we placed a few small strategic bets for the future.
We continue to execute our capital deployment plan through
significant share repurchases with plans for more. I'm feeling
pleased with the progress we've made, and while much remains to be
done, I'm feeling very positive about the future. Now let me turn
it over to Jeff for a detailed look at the quarter's financial
results. Jeff? Jeff Henderson - Cardinal Health, Inc. - CFO Thanks,
Kerry. Good morning, everyone. On today's call I'll discuss second
quarter results, review our key value drivers, and summarize our
fiscal 2007 financial targets and goals. Additionally, I'm going to
spend a minute providing you with our internal assessment for the
acquisitions we've done over the past few years, which is something
we plan to do on a regular basis going forward. Finally, I'll
conclude with some specific details around the PTS divestiture and
just a few comments on the changes to our existing segment results.
Let's start with the consolidated second quarter results. Please
note that my comments will reflect the financial results from
continuing operations on a non-GAAP basis. And keep in mind that
our PTS business is treated as discontinued operations in
www.streetevents.com Contact Us 3 2007 Thomson Financial.
Republished with permission. No part of this publication may be
reproduced or transmitted in any form or by any means without the
prior written consent of Thomson Financial.
5. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call these financials.
The definition is at the end of the slide describing detail how we
are calculating these non-GAAP metrics. Overall revenues were up
13% to 21.8 billion, driven by very strong demand across each of
our four business segments. Operating earnings were 544 million, an
increase of 16% over the same period last year. Earnings from
continuing operations for the quarter were 341 million, up 15% from
prior year results of 297 million. Diluted EPS for the quarter was
$0.83 compared to $0.69 last year, up 20%. A contributing factor to
our strong earnings growth was continued focus on expense control.
Although total SG&A increased 8% for the quarter compared to
the same period last year, I should point out that about 3.5 % of
this growth was attributable to recent acquisitions and this growth
also reflects a continued investments we are making in product
development and other growth initiatives particularly in our CTS
and MPM segments. Interest expense in the quarter was about 32
million. Approximately $10 million of interest and other has been
allocated to discontinued operations within PTS. I would expect
interest and other to be similar in Q3 or about 35 million; however
this amount could increase by about $10 million in our fourth
quarter assuming that PTS transaction closes in Q4, as this amount
will no longer be classified as discontinued operations. Our
effective tax rate for the quarter was 34.3%. With PTS results
moved to discontinued operations, our recurring effective tax rate,
excluding special items and impairment charges increases by
approximately 40 basis points. As a result, we expect our effective
tax rate for the full fiscal year 2007 to be about 32%, up from the
31.6% I mentioned last quarter. Although as I also mentioned last
quarter, we will see some fluctuation in this rate from quarter to
quarter throughout fiscal '07. Operating cash flow for the quarter
was a negative 52 million and returned equity was 15.2% up 60 basis
points over the same period last year. Our operating cash flow in
the quarter was negatively impacted by the pay off of the 550
million balance remaining under our AR securitization program.
Turning to the next slide, I want to point out to you specific
guidance that had an impact on current and prior year operating
results and earnings per share, specifically special items,
impairment charges and other, and non-recurring and other items. As
I mentioned several times in the past, my goal is to simplify our
presentation with the elimination of most non- recurring items and
we have done so throughout the fiscal year. First, let me quickly
review the special items. During the quarter, special items totaled
$20 million or 13 million after-tax impacting diluted EPS by $0.03
per share versus the same $0.03 per share in Q2 of last year.
Included in this year's amount were costs associated with
restructuring operations, charges to integrate acquired companies
primarily Doleman and Alaris, SEC investigation costs, and other
miscellaneous items. The next slide is impairment charges and other
items. During the quarter impairment charges were 13 million, also
the same 13 million after-tax, impacting diluted EPS by $0.03 per
share, compared to $0.00 the per share in Q2 last year. These
impairment charges in the quarter primarily related to an
impairment in investment in the global healthcare exchange, an
Internet based healthcare exchange formed several years ago by
multiple healthcare product manufacturers. Turning to non-recurring
charges I want to remind you that in our second quarter last year
we incurred a $3.5 million credit taken within our Healthcare
Supply Chain Services Pharmaceutical segment, which was an
adjustment related to a charge taken in the first quarter of that
same year. For clarity, this credit is included in our non-GAAP
diluted EPS of $0.69 in Q2 of last year. Again, there were no
non-recurring items recorded in the second quarter of this year.
Now I'd like to turn to the performance of the individual business
segments. As I discuss the results of each of our four segments
please note that the beginning of this quarter we have begun to
burden our segment results including both current and prior year
with equity compensation expense which currently has a positive
impact on our segment growth rates as equity expenses declined year
on year. For perspective total equity comp expense booked in Q2
this year was 33 million versus $47 million in Q2 of last year.
I'll discuss some more details at the end of my presentation but I
want to assure you that we fully intend to disclose the impact of
equity expense for each of our segments so you can determine the
earnings the earnings growth rates excluding this expense.
Healthcare Supply Chain Services Pharmaceutical, revenue for the
second quarter increased 13% to $19.2 billion. Revenue growth
within this segment was driven by strong growth in the core
pharmaceutical distribution business across all customer
www.streetevents.com Contact Us 4 2007 Thomson Financial.
Republished with permission. No part of this publication may be
reproduced or transmitted in any form or by any means without the
prior written consent of Thomson Financial.
6. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call segments, which
increased revenue 18% over the prior year. This revenue growth was
due to both good growth within our core direct store delivery
business which grew 14% and continued increases in bulk customer
sales. Please recall this segment now includes our Medicine Shoppe
business, nuclear pharmacy, Specialty Pharmacy Services including
the acquisition of Specialty Scripts going forward and Martindale
and Beckloff Associates, formerly part of PTS. Regarding our
Specialty Distribution business, you might recall that in 2006, we
divested the majority of our oncology focused Specialty
Distribution business which negatively impacted our growth rates in
this segment over the prior year as we saw revenue decline over
$500 million in this business in the second quarter of this year
compared to last. Operating earnings were 328 million, an increase
of 19% over the prior year period. I'll remind you that our results
in the second quarter of fiscal 2006 included a $3.5 million
non-recurring credit related to vendor credits in prior periods.
There was no LIFO impact to earnings in Q2 of this year. However,
last year, we had a $13 million LIFO credit which favorably
impacted earnings in the prior year. Strong growth in generics
expense controls, and acquisition synergies contributed to margin
expansion and solid operating earnings growth, which was partially
offset by lower pricing in the renewal of several large customer
agreements. I should also point out that the timing of certain
generic launches and branded drug price increases benefited our
operating results in the second quarter. A portion of which
otherwise would have likely occurred in our fiscal third quarter.
Strong earnings growth in our nuclear pharmacy business helped
offset an earnings decline in Specialty Distribution, again
associated with the sale of the majority of this business. Equity
compensation expense was $13.7 million in Q2 of this year compared
to $15.3 million in the same quarter last year. As you know,
specifically within our Healthcare Supply Chain Services business,
we also measure economic profit margin. We have begun to use
economic profit margin as a metric to combine both the impact to
the income statement and the balance sheet as a measure of our
performance. Within Supply Chain Pharmaceutical, economic profit
margin increased 9 basis points to 82 basis points in the quarter
compared to 73 basis points in the prior year. Year-to-date,
economic profit margin has increased 12 basis points over the prior
year to 91 basis points. The improvement in the second quarter was
primarily driven by earnings growth as total tangible capital
remained fairly stable. For this segment, days of inventory
declined two days compared to the second quarter of last year.
Healthcare Supply Chain Services medical segment revenue for the
quarter was $1.9 billion, up 6% over the prior year. Revenue growth
was due to strong demand in our laboratory business, both in
capital equipment sales and consumables as well as our product
brand product portfolio and continued momentum with surgery center
customers and within our Canadian Medical Products Distribution
business. I mentioned last quarter of a negative impact on this
business segment from the customer service consolidation. I would
say that we're making considerable improvements here; however this
transition continues to negatively impact our results. Operating
earnings for the quarter were $78 million, up 12% over the same
period last year. Earnings growth was primarily due to a strong
focus on cost controls and expense leverage due to various One
Cardinal Health initiatives, including facility consolidations and
back office consolidation efficiencies such as our customer service
consolidation. Equity compensation expense was 8.1 million in Q2 of
this year compared to 9.9 million in the same quarter last year.
For our healthcare Supply Chain Services medical segment, economic
profit margin declined 6 basis points over the prior year to 1.12%;
however EP margin in the Second quarter increased 56 basis points
sequentially over the first quarter. The decline in EP margin
compared to the prior year was driven by an increase in total
tangible capital, mostly working capital. While we certainly
continue to expect earnings growth in the full fiscal year, we also
see opportunities to lower our tangible capital in this business,
which should result in a stable EP margin trends year-over-year.
Clinical Technologies and Services segment revenue for the quarter
was 662 million, up 10% over the prior year, and operating earnings
were [910] million, up 16% compared to the prior year. You'll
recall that our first quarter results were negatively impacted by
delays in two new products, MedStation 3500 and the Alaris PCU
version 1.5. While the Alaris product was launched at the end of
Q1, the Pyxis med station was not fully released until our second
quarter. Both products contributed to the improved results as very
strong demand for both Pyxis and Alaris products contributed to
revenue growth. We expect demand to remain strong as [Inaudible]
contracts for Alaris products and Pyxis medication and supply
products were up significantly from both the prior year and
sequentially. www.streetevents.com Contact Us 5 2007 Thomson
Financial. Republished with permission. No part of this publication
may be reproduced or transmitted in any form or by any means
without the prior written consent of Thomson Financial.
7. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call I want to
specifically point out our Pyxis supply business which is seeing
very strong demand and growing quite well. While a relatively small
contributor today, we expect these products to contribute more
meaningfully in the near future, helping to drive sustainable long
term growth. Operating earnings growth was driven by both strong
revenue growth and continued synergies from the integration of
Alaris. Earnings were also positively impacted by continued
improvements within our Pharmacy Management Services business.
Equity compensation expense was 10.7 million in Q2 this year
compared do 12.4 million in the same quarter last year. I should
also point out that no change was made to the SE pump recall
reserve of 13.5 million that was established last quarter. Somewhat
dampening earnings growth were continued investments we are making
in the business to ensure long term value creation, specific
examples include the continued investments in product quality and
customer service, where we have seen meaningful improvements in
customer satisfaction over the past several months. Additionally we
continue to invest heavily in R&D, and are making great
progress in our all medication strategy which includes Alaris and
Pyxis products as well as a recently acquired Care Fusion bedside
verification product. Finally, we're investing in international
infrastructure to help accelerate our international growth. Medical
Product Manufacturing revenue increased 15% to 455 million and
operating earnings increased 21% to 51 million. Revenue growth was
driven by solid balanced results across all businesses within the
segment including infection prevention and medical specialties,
both domestically and internationally. Earnings growth was
positively impacted by operational excellence initiatives and the
impact of facility restructuring. Additionally the business was
able to offset continued raw material cost pressures through
contract and pricing discipline. Equity compensation expense was
7.7 million in Q2 of this year compared to 9.1 million in the same
quarter last year. Similar to CTS, our Medical Products
Manufacturing business continues to invest in new product R&D
and international infrastructure to drive future growth.
Integration of Denver Biomedical is ahead of plan and is
contributing better than expected to this segment. Once again let
me touch on our key value drivers consisting of what we've been
talking about over the past 18 months or so. First is operating
growth, which will be led by strong revenue growth in a growing
healthcare revenue pool, driven by strong demand for our products
and services. Within the Healthcare Supply Chain Services segments,
leverage of our scale, capital efficiency, and operational
excellence should drive economic profit margin expansion. Within
the Pharmaceutical and Medical Products segments, operational
excellence, product innovation and international expansion should
drive operating margin expansion. Overall, we see SG&A
moderation driven largely by our One Cardinal Health program and
declining equity compensation. Next is style sheet management. We
have an increasing focus on return on capital and economic profit
in our investment and operational decisions. Not only is this how
we manage the businesses. It is one of the measures by which our
management team is compensated going forward. Also mention
continued portfolio optimization here which is best evidenced by
our announced sale of PTS. One other Balance sheet item of note is
accounts receivable. During the quarter we paid off the remaining
balance of our A R securitization facility which was was $550
million. The impact of this was increased accounts receivable by
the same amount. So year-over-year, while total days sales
outstanding increased, much of this increase was due to the pay off
of the AR facility. Finally, disciplined capital deployment. Again,
nothing new here. Consistent with last year, our plans are for 25%
of our operating cash flow to be utilized for internal capital
investments, 20% for smaller tuck-in acquisitions and about 50% is
expected to be returned to shareholders and I'll remind you we want
to maintain the flexibility to selectively make larger acquisitions
in the medium term that make strategic sense for the Company but in
the short-term here, you should expect us to deploy capital
consistent with these parameters. I think our actions in the first
half of this fiscal year are right in line here. During the year,
in addition to internal capital deployment, we have repurchased
more than $925 million of Cardinal stock and we acquired MedMind,
Care Fusion, and Specialty Scripts , which are all perfect examples
of the a type of acquisitions we're looking at. Relatively small,
tuck-in acquisitions that enhance www.streetevents.com Contact Us 6
2007 Thomson Financial. Republished with permission. No part of
this publication may be reproduced or transmitted in any form or by
any means without the prior written consent of Thomson
Financial.
8. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call our product
offerings for customers and manufacturers. In total, our focus,
discipline, and focus on return on capital are allowing us to drive
organic growth and that we believe optimize shareholder value. Now
I'd like to discuss our fiscal financial targets, fiscal 2007
financial targets and goals slide. Targets and goals are exactly
the same as I discussed on November 30, when we announced the
planned sale of PTS. For 2007, on a consolidated basis we continue
to expect revenue to be at or above the high end of our long term
range of 8 to 10%. Non-GAAP diluted earnings per share is expected
to be $3.25 to $3.40 per share which excludes the impact of the
proceeds from the planned sale of PTS. Within the individual
segments, fiscal 2007 guidance remains the same. One thing I want
to point out here is the impact of allocating equity compensation
to the segment results which will have a favorable impact on our
segment growth rates. The segment earnings growth rates target on
the slide exclude any impact of equity compensation allocation. As
Kerry referenced, and I mentioned up front, it is our intention to
going forward to provide you with feedback on how we are
progressing on the acquisitions we have done over the past several
years. We have admittedly had mixed results with some of our
acquisitions completed a few years back and based on that we've
adopted increasingly rigorous decision-making, integration, and
review process for all transactions. For the purpose of this
presentation I'll focus on the transactions we have closed over the
past three years. This very disciplined internal approach of
retrospectively reviewing all transactions, we'll actually really
deal with the Board as well is one that we take quite seriously and
I want to share with you a summary of our findings. While we look
at several factors, our primary measure is the actual economic
profit contribution delivered or our current forecast for that
economic product contribution in year three compared to
expectations at the time of the acquisition for the third year
following the date the transaction closed. With the exception of
Snow and Pincer, a relatively modest investment made in 2004 by our
MPM segment I'd say that our recent acquisitions all receive a
positive grade in this regard and in total we are exceeding our
economic profit generation goals. A meaningful contributing factor
to our success can be attributable to the dedicated focus we place
on merger integration which includes synergy tracking and customer
integration measurement. We first establish a dedicated team of
folks at a corporate level to focus solely on merger integration
just after the acquisition of Alaris and I believe the focus has
paid off. Two final but important items Ike lie to cover. I want to
take a few minutes to share a few semi details around the PTS
divestiture and how this impacts our fiscal 2007 guidance as well
as briefly discuss some changes to our segment reporting. First,
let me discuss the PTS divestiture. We are extremely happy with the
way the process has been executed. As I previously mentioned,
depending on the specific timing of the deal closing, we will
expect the after-tax proceeds from the sale to add materially to
our fiscal 2008 EPS but I'm not going to try to quantify that exact
amount at this time. Regarding timing, we would expect the
transaction to close some time during our fiscal fourth quarter. As
it relates to our fourth quarter, to the extent there is a positive
impact due the investment of the proceeds, I would anticipate that
any such benefit would be offset by our planned modest contribution
to the Cardinal Health Foundation, focused on supporting
productivity improvements and patient safety within healthcare.
Based on the way the transaction is being structured, we now
estimate our tax basis at over $3 billion, so a significant amount
of the proceeds will be available to acquire shares, which is our
current expectation for the use of the proceeds. Including
discontinued operations during our second quarter in addition to
the net operating results from operations of the entities included
in disc ops, we booked a deferred tax asset or benefit of
approximately approximately $425 million. I should point out this
benefit will be offset by a similar tax expense on any potential
book gain when the transaction closes, but into fatality this
should be a very tax efficient transaction for Cardinal. Now
turning to our segment reporting. Due to the divestiture of
Pharmaceutical technology and Services, some of the corporate
expenses that were previously absorbed by PTS will now be allocated
to our remaining four business segments. These amounts have all
been allocated for our prior periods and included in the segment
results reported in our press release and my presentation today.
During our second quarter approximately $12 million of incremental
corporate expenses previously allocated to PTS www.streetevents.com
Contact Us 7 2007 Thomson Financial. Republished with permission.
No part of this publication may be reproduced or transmitted in any
form or by any means without the prior written consent of Thomson
Financial.
9. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call have been allocated
to the remaining four segments and $12 million of corporate costs
have been allocated to PTS which again is included in discontinued
operations. In the same period last year about $10 million of
incremental corporate expenses were allocated to the remaining four
segments and about 11 million was allocated to PTS. Being as we had
to make the change anyway and restate prior periods, we also
decided to implement another change, burdening our segments with
equity compensation expense and that's giving an even more complete
view of the total cost of running the segments after corporate
allocations and other costs. As I previously said it is our
intention to be extremely transparent as to the amount of equity
compensation allocated each segment so you can calculate our
earnings growth rates excluding this amount if you so choose. I
understand that changes in the way we report results are not
preferred by anyone including myself, it was required to do the
divestiture of PTS and we determined that including equity
compensation at this time made sense as well. As previously stated
is our intention of providing historical data by quarter, restated
to reflect these changes some time during our third fiscal quarter.
Thanks, everyone. Kerry? Kerry Clark - Cardinal Health, Inc. -
President, CEO I think we're open for questions. QUESTIONS AND
ANSWERS Operator [OPERATOR INSTRUCTIONS] And your first question
comes from the line of Christopher McFadden of Goldman Sachs.
Please proceed. Christopher McFadden - Goldman Sachs - Analyst
Thank you. Good morning, and congratulations on the nice quarterly
results to everyone there. Kerry Clark - Cardinal Health, Inc. -
President, CEO Thank you. Christopher McFadden - Goldman Sachs -
Analyst Two questions, if I might. First, Jeff, do you think you
could give us a sense and I know we talked about this in --
following the first fiscal quarter, what contribution on a net
basis you think the One Cardinal initiatives made here in the
second quarter and do you still feel comfortable that you're on
pace for the 2008 overall contribution that you have talked about
historically? And then secondly, as you're obviously aware, your
customer CVS is in some form of discussions or trying to finalize a
transaction with CareMark. If that transaction were to come to
fruition, what impact, if any, do you think it would have on the
distribution volume that you have as a part of your relationship
with CVS? Thanks. Jeff Henderson - Cardinal Health, Inc. - CFO
Thanks, Chris, this is Jeff. I'll answer your first question and
then I'll let Mark Parish who is joining us today answer the
second. Regarding One Cardinal Health, as I said in our prior
earnings call, we anticipate in fiscal '07 that we will have
achieved about 70% of the fiscal '08 run rate of $500 million of
savings. That would equate to about $350 million savings for our
full year fiscal www.streetevents.com Contact Us 8 2007 Thomson
Financial. Republished with permission. No part of this publication
may be reproduced or transmitted in any form or by any means
without the prior written consent of Thomson Financial.
10. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call '07, again, that
would be compared to fiscal 05 base period, so if you divide that
by four, you could estimate about $90 million of benefit in Q2
versus same period two years ago. I think that's a rough way of
looking at it. Christopher McFadden - Goldman Sachs - Analyst And
we should think, just to clarify, Jeff, that the trajectory through
the quarter of fiscal '07 will be sort of equally distributed or is
there a ramping up that we should anticipate? Jeff Henderson -
Cardinal Health, Inc. - CFO I would expect some ramping up but
again as I said in the Q1 call, Chris, not all of that is flowing
to the bottom line because we've made a decision to reinvest some
of it back in the business particularly within our MPM and CTS
businesses and we're making substantial investments for new
products as well as international expansion, but I would say
generally, it's an upward ramp over the course of the year.
Christopher McFadden - Goldman Sachs - Analyst And do you think net
of those investments that was a net contribution to FQ2? Jeff
Henderson - Cardinal Health, Inc. - CFO Yes, I do. Okay, thank you.
Thanks. Mark you want to answer? Mark Parish - Cardinal Health,
Inc. - CEO, Healthcare Supply Chain Services Yes, Chris, relative
to the CVS-CareMark announcement, we're actually very positive
about that for the CVS business. I think it's going to drive
certain amount of organic growth for CVS which we believe we will
benefit from, so we think it's a positive if they are able to
conclude that transaction successfully which certainly appears that
they may be but depends on who you're talking to. Relative to the
buying behavior of CVS, CVS is a very efficient buyer today and we
have a very efficient contract in place with them that runs through
the middle of 2008, so we don't see any immediate changes there.
Christopher McFadden - Goldman Sachs - Analyst How about relative
to their mail order sites, and the potentially new mail order sites
that they would incorporate in this combination? Mark Parish -
Cardinal Health, Inc. - CEO, Healthcare Supply Chain Services Yes.
The way their business is separated today and the way they manage
that business, we actually do not service CVS's mail order
facilities today, Chris. Those are serviced by one of our
competitors. Christopher McFadden - Goldman Sachs - Analyst
Opportunity? www.streetevents.com Contact Us 9 2007 Thomson
Financial. Republished with permission. No part of this publication
may be reproduced or transmitted in any form or by any means
without the prior written consent of Thomson Financial.
11. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call Mark Parish -
Cardinal Health, Inc. - CEO, Healthcare Supply Chain Services
Absolutely. Christopher McFadden - Goldman Sachs - Analyst I'll
stop there. Thank you. Mark Parish - Cardinal Health, Inc. - CEO,
Healthcare Supply Chain Services Thank you. Jason Strohm - Cardinal
Health, Inc. - VP, IR Next question? Operator? Operator? Operator
Sorry. Your next question comes from the line of Tom Gallucci of
Merrill Lynch. Please proceed. Tom Gallucci - Merrill Lynch -
Analyst Good morning, thank you. Just wondering about capital
deployment, sort of two aspects of it. Buyback, clearly over 3
billion of after-tax proceeds from PTS seems very positive to us.
Is there any color you can give on the pace that you might perform
those share repurchases, and then I think at your Investor Day, you
had suggested you might be ready for acquisition some time this
year and then Jeff, I think you mentioned in your prepared remarks
possibly larger acquisitions in the medium term, so can you expand
on those thoughts as well? Jeff Henderson - Cardinal Health, Inc. -
CFO Let me take the first question, Tom, good morning. Regarding
the buyback, obviously, we have to close the deal first and get the
proceeds and if all goes well we expect that to happen in Q4 of
this year and following that, as we said, we're committed to using
those proceeds to buyback shares. We expect to do it on a timely
basis but I'm not in a position today to say the exact timing, but
I would say it will happen and our goal is not to drag it out over
an extended period. Kerry Clark - Cardinal Health, Inc. -
President, CEO Tom, this is Kerry. Just talking to the future, we
mentioned, Jeff mentioned, the medium term and the short-term, we
continue to focus on putting together a string of good quarters and
operating efficiently and looking at smaller tuck-in acquisitions,
so we don't have any immediate plans or programs or anything in
hand right now that on a big acquisition that you should expect, so
we're going to focus on continuing to do what we've been doing and
continuing to do that for a few more quarters. Tom Gallucci -
Merrill Lynch - Analyst Okay, if I could ask a follow-up there.
Conceptually on bigger deals potentially down the road, would they
theoretically be things that you could tuck into the current
segments or could you possibly look at new legs to the stool?
www.streetevents.com Contact Us 10 2007 Thomson Financial.
Republished with permission. No part of this publication may be
reproduced or transmitted in any form or by any means without the
prior written consent of Thomson Financial.
12. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call Kerry Clark -
Cardinal Health, Inc. - President, CEO Well, I think at the moment,
we're really focusing on building up our current portfolio of
products and services that are in healthcare, productivity, and
safety, so I would think we're going to be more comfortable in the
general areas in which we have a lot of expertise. Tom Gallucci -
Merrill Lynch - Analyst Okay, thank you. Jason Strohm - Cardinal
Health, Inc. - VP, IR Operator, next question, please? Operator
Your next question comes from the line of Glen Santangelo of Credit
Suisse. Please proceed. Glen Santangelo - Credit Suisse - Analyst
Yes, Kerry, just one more follow-up question on the acquisition
stuff. It seems like you've done a pretty thorough review here of
all of the acquisitions over the past few years and it seems like
you've only identified one which may be under performing your
targets. Is it fair to say that almost a year in now you've done a
complete review of the business and you pretty much feel
comfortable with what you have at this point? Would it be
reasonable to think that there could be possible divestitures down
the road or are we good for now? Kerry Clark - Cardinal Health,
Inc. - President, CEO Tom, I would say we're substantially complete
in the portfolio management area. There may be some other things
but we're substantially complete. Glen Santangelo - Credit Suisse -
Analyst Okay, thanks for the comments. Jeff Henderson - Cardinal
Health, Inc. - CFO I would also add to that as qe've said many
times before that the process of portfolio optimization is an
ongoing one. We review all of our business units on a regular basis
and we continue to assess them based on strategic fit, growth
potential, and return on capital, so, I don't think the process of
portfolio optimization ever really ends. Jason Strohm - Cardinal
Health, Inc. - VP, IR Operator, next question, please?
www.streetevents.com Contact Us 11 2007 Thomson Financial.
Republished with permission. No part of this publication may be
reproduced or transmitted in any form or by any means without the
prior written consent of Thomson Financial.
13. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call Operator Your next
question comes from the line of Ross Muken of Deutsche Bank. Please
proceed. Ross Muken - Deutsche Bank - Analyst Hello, gentlemen.
Kerry Clark - Cardinal Health, Inc. - President, CEO Hello. Ross
Muken - Deutsche Bank - Analyst Your clinical business, you showed
a very nice turnaround in the quarter and certainly, it seems as if
there's some exciting new product developments undergoing in that
division. Could you talk a bit about the new system you're debuting
there and sort of the unique nature of that and should we continue
to expect R&D in that division to focus on similar-type
platforms for patient safety, similar to what you're going to be
debuting shortly? Kerry Clark - Cardinal Health, Inc. - President,
CEO Dave, do you want to take that question? Dave Schlotterbeck -
Cardinal Health, Inc. - CEO, Pharmaceutical, Medical Products I
will, thank you. We plan to demonstrate next month a fully
integrated medication administration delivery system that I believe
will be the most complete and the most integrated offering
available from any company worldwide, and not only will this
validate the administration of medication to the patient but it
will also allow populating the hospitals, electronic medication
administration record, and if they do not have electronic
administration medication records available, we will be able to
provide that, so I'm very excited about this new product offering.
It will also provide significant insight into the infusion delivery
for all the patients in the institution, so, and then the answer to
your second question or second part of your question is yes, you
can expect to see ongoing levels of significant investment in
R&D because Clinical Technologies and Services really is a
technology business. Ross Muken - Deutsche Bank - Analyst Great,
thank you very much. Operator Your next question comes from the
line of Larry Marsh of Lehman Brothers. Please proceed. Larry Marsh
- Lehman Brothers - Analyst Thanks. First of all I think it's great
to see how quickly you guys are moving to completion of the PTS
sale. It's a big positive. I have a clarification and a quick
question. The clarification for Jeff, just if you add up the four
equity comp expenses by division in your presentation, I'm getting
40 million. Is there some sort of net out account that I'm missing
in that in the quarter? www.streetevents.com Contact Us 12 2007
Thomson Financial. Republished with permission. No part of this
publication may be reproduced or transmitted in any form or by any
means without the prior written consent of Thomson Financial.
14. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call Jeff Henderson -
Cardinal Health, Inc. - CFO First of all, they've been allocated
based on budget, Larry but if you're of trying to get them to add
up to--. Larry Marsh - Lehman Brothers - Analyst 33? Jeff Henderson
- Cardinal Health, Inc. - CFO Yes, the PTS piece, obviously isn't
there so that would get you to the -- probably the total that you
were expecting to see. Larry Marsh - Lehman Brothers - Analyst So,
okay. I just, so you're allocating the former PTS corporate
expenses to the other three divisions this quarter; is that right?
Jeff Henderson - Cardinal Health, Inc. - CFO No. Maybe I didn't
understand your question, Larry. If you could repeat it. Larry
Marsh - Lehman Brothers - Analyst Okay, I'm sorry. Just if you take
-- you're allocating corporate expense by division this quarter and
in your presentation the four divisions you highlight, I add up to
$40 million, and I know your net equity comp expenses you suggest
was 33 million, so I'm just looking for a reconciliation and I can
do that off line if that's easier. Jeff Henderson - Cardinal
Health, Inc. - CFO Oh, okay. Because there is an offset at the
Corporate level because we allocate based on budget and then to the
extent there are fluctuations and actuals in at any given quarter
there is a trueup at the Corporate level, Larry, so in this
particular case it was a negative trueup. Larry Marsh - Lehman
Brothers - Analyst Okay, and then the question is for Kerry, maybe
elaboration on your Specialty acquisition. You're suggesting a
bigger opportunity, really want to compare and contrast that
opportunity from your scale in the distribution business of
Specialty products where you've sold that business to OT and what's
the big difference, and then who's running that set of divisions
under Mark and is that going to be changing? Kerry Clark - Cardinal
Health, Inc. - President, CEO Well, if you don't mind, Larry, I'll
have Mark talk to those two questions. www.streetevents.com Contact
Us 13 2007 Thomson Financial. Republished with permission. No part
of this publication may be reproduced or transmitted in any form or
by any means without the prior written consent of Thomson
Financial.
15. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call Larry Marsh - Lehman
Brothers - Analyst Sure. Mark Parish - Cardinal Health, Inc. - CEO,
Healthcare Supply Chain Services Thanks, Kerry. Larry, the
Specialty Scripts business is very specifically focused on the
Pharmacy Services to the patient, and represents an extension of
services that we think is critical to our ability to be able to
compete for some of the exclusive and semi exclusive distribution
networks that manufacturers are creating for these products. It
contrasts somewhat, but -- with the Specialty distribution business
but I would add that there is a blurring in this marketplace now
between Specialty distribution and Specialty pharmacy. The old
Specialty distribution business that we have that is now integrated
into the OTN business is specifically focused on the oncology
clinics and delivering product directly to the physicians in the
oncology space, so they're two different businesses but relative to
the capacity that we have -- or the capabilities I should say that
we need to have, we feel in order to be able to serve the
manufacturers the way we would like to, Specialty Scripts gives us
that capability, and the Specialty distribution business to
oncology is not as critical. Larry Marsh - Lehman Brothers -
Analyst And just who joining those sets of businesses for you,
Mark? Mark Parish - Cardinal Health, Inc. - CEO, Healthcare Supply
Chain Services We haven't made that announcement yet, Larry, but we
do have an internal individual who will head up that unit for us
and we are also very excited that the management team from
Specialty Scripts will continue to be involved and they are
excellent individuals that are very knowledgeable in this business.
Larry Marsh - Lehman Brothers - Analyst Okay. And that's a time
when you hope to get ahead of your drug business, Mark? Or is that
yet to be determined? Mark Parish - Cardinal Health, Inc. - CEO,
Healthcare Supply Chain Services That, we are still in the process
of talking to candidates about that particular position. That
Specialty business will report into that position, Larry. Larry
Marsh - Lehman Brothers - Analyst Okay, great. I'll stop there.
Thank you. Operator Your next question comes from the line of Ricky
Goldwasser of UBS. Please proceed. Ricky Goldwasser - UBS - Analyst
Yes, hi. A couple of questions. First of all, with AMP preliminary
guidance out there, can you share with us kind of what's your
initial take away on how this could impact your business and your
customers, and then on the Specialty Script business, should
www.streetevents.com Contact Us 14 2007 Thomson Financial.
Republished with permission. No part of this publication may be
reproduced or transmitted in any form or by any means without the
prior written consent of Thomson Financial.
16. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call we look at it as
kind of just you initially testing the water and then potentially
looking to further expand in this area or is this kind of like
where you want to be? Kerry Clark - Cardinal Health, Inc. -
President, CEO Ricky, I'll take the first -- the questions in order
here. Relative to AMP, certainly there's been a lot of discussion
about that and we're in a period right now where comments are being
made to CMS regarding the final definition. We are working closely
with our customers and in particular through our trade associations
with work with CMS but also directly with CMS in certain situations
to be able to help clarify our concerns relative to the definition
that is out there today, and that process is going to be ongoing
for a few more weeks, so it's early to tell what the specific
impact is going to be but we certainly do anticipate that we'll be
working closely with our customers in trying to help them improve
their situation by getting the rule right first and foremost,
because we believe that the language and the rule right now is
probably flawed in terms of reflecting the actual prices that
retail pharmacy can achieve in business. Second question, relative
to Specialty, again, this is a very important capability we think
is critical to being able to participate to the level that we need
to participate in the Specialty sector. When you look at that part
of the business, the Pharmaceutical business in the United States
overall, it is the fastest growing segment of the portfolios of
manufacturers. If you look up the R&D pipeline, products coming
out that you would call Specialty products are the lion's share of
the sales that are expected out of the new products coming out over
the next few years so this is an important move for us to make sure
that we can continue to participate in a very important space in
the industry. Ricky Goldwasser - UBS - Analyst Okay, and will you
work with -- some of your clients have Specialty pharmacy
capabilities of their own, so do you envision a day where you can
work with them there or are you going to compete with them for that
business? Kerry Clark - Cardinal Health, Inc. - President, CEO We
actually envision the opportunity to work with them. The niche that
Specialty Scripts plays in the marketplace is very high touch
Services extended to patients through the Specialty pharmacy with
very intensive needs for data collection and clinical intervention,
and we believe that that is a niche in the marketplace that is a
highly specialized one and one that is complementary to some of the
things that our major customers are doing and I would point out
that amongst the three major wholesalers, each of the three major
wholesalers are participating in different ways in the Specialty
business. Jason Strohm - Cardinal Health, Inc. - VP, IR Operator,
next question, please? Operator Your next question comes from the
line of Lisa Gill of JP Morgan. Please proceed. Lisa Gill - JP
Morgan - Analyst Thanks very much and good morning. Kerry, I think
in your prepared remarks you talked about the fact that
international now is 12% of your revenue. Can you talk about what
specific divisions that's coming from and where you see the growth
opportunities? www.streetevents.com Contact Us 15 2007 Thomson
Financial. Republished with permission. No part of this publication
may be reproduced or transmitted in any form or by any means
without the prior written consent of Thomson Financial.
17. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call And then secondly,
Dave, I was wondering if you maybe you could talk about the Alaris
recall of the SE pump and where we stand on that? Kerry Clark -
Cardinal Health, Inc. - President, CEO Lisa, hi. The revenue grew
12% but it's only 2% of our total, and where we are really focusing
on is establishing what I'll call, One Cardinal Health
organizations in Canada, the UK, France, and Germany, with a view
to bring and integrate our offerings mostly on CTS, MPM, and
surgical pre-kits, presourcing products into offerings that are
tailored and work within the health systems in each of these
countries, so last summer, we announced our Canadian country
manager. We just announced our UK country manager and we're getting
ready to announce our German country manager and we're pulling
together these integrated programs and even in Canada, where we're
starting to get some additional business because we're showing up
as One Cardinal Health. So that's what we're primarily focused on
in the international area. Dave Schlotterbeck - Cardinal Health,
Inc. - CEO, Pharmaceutical, Medical Products And to your question,
Lisa, on the Alaris recall, we continue to work closely with the
FDA in making sure that we will meet their requirements. We have
submitted and obtained approval on a technical change to the
majority of the products that are positioned in the field. We now
need to submit the recall, the detailed recall plan and so I feel
like we're in a position of having made very good progress in
dealing with this issue. Lisa Gill - JP Morgan - Analyst And what
do you think the timeline is? Dave Schlotterbeck - Cardinal Health,
Inc. - CEO, Pharmaceutical, Medical Products It's a little hard to
say. I'm hopeful that we may be in a position to give a lot more
information relatively soon. Kerry Clark - Cardinal Health, Inc. -
President, CEO Lisa, I would just add that we have not made any
assumptions on the returned sale of SE and the balance of the year.
Lisa Gill - JP Morgan - Analyst Okay, great. Thank you. Jason
Strohm - Cardinal Health, Inc. - VP, IR Operator, next question?
Operator Your next question comes from the line of Sandy Draper of
JMP Securities. Please proceed. www.streetevents.com Contact Us 16
2007 Thomson Financial. Republished with permission. No part of
this publication may be reproduced or transmitted in any form or by
any means without the prior written consent of Thomson
Financial.
18. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call Sandy Draper - JMP
Securities - Analyst Thanks. Most of my questions were asked, but
just a quick one, Jeff. I'm trying to understand the accounting
side of pulling some interest expense and pushing it down into
discontinued ops but then pulling it back up into continuing ops
with the sale of PTS. Is it because there are bonds that are
specifically backed by PTS assets or revenue, if you could just
help me out there, that would be great. Jeff Henderson - Cardinal
Health, Inc. - CFO No, it's more because of a quirk in the way
accounting for discontinued operations works, Sandy, in that once
you declare something discontinued ops, as long as you have it, you
allocate a certain portion of your expenses, including interest
expense to that segment while it's still part of the overall
entity, but recorded in discontinued ops, and then once you sell
the entity, obviously it's no longer recorded in discontinued ops
so unless that interest expense goes away, it then comes back on
the books of the continuing operations. So we don't have any
intentions of reducing our debt level once the PTS divestiture
happens, so it just comes back on our books, so it's more just
moving back and fourth between disc ops and continuing ops. Sandy
Draper - JMP Securities - Analyst So that makes sense. So there's
no connection to the actual revenue business and no debt is going
to go with PTS? Jeff Henderson - Cardinal Health, Inc. - CFO
Correct. Sandy Draper - JMP Securities - Analyst Okay, great.
Operator You're next question comes from the line of [David Biel]
of Morgan Stanley. Please proceed. David Biel - Morgan Stanley -
Analyst Thanks good morning. Just a question on the guidance and
I'm sorry if I missed any of this in your prepared remarks but if
we assume $1.57 is the right apples-to-apples first half comparison
for guidance, the current range would imply anywhere from no
sequential growth in earnings to fairly robust growth in the next
couple of quarters. Could you walk us through what the key swing
factors are between the high end and low end and then call out the
unique items we should anticipate for the balance of the year? Jeff
Henderson - Cardinal Health, Inc. - CFO I'm not sure I want to get
into that level of detail, David. Let me say that as a general
policy, we don't change our guidance over the course of the year,
so for those of you who are expecting us to tighten it, et cetera,
again, as a general policy, we set it once at the beginning of the
year, unless there's an extraordinary reason to change it we
maintain it, but we've left the guidance as it is. We're
comfortable with that range. As Kerry said in his opening remarks
we've had good momentum in the first half. We're
www.streetevents.com Contact Us 17 2007 Thomson Financial.
Republished with permission. No part of this publication may be
reproduced or transmitted in any form or by any means without the
prior written consent of Thomson Financial.
19. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call hopeful we can
continue that momentum in the second half and I can't really point
to any specific ups or downs of any note other than the general
business challenges that we face on a day-to-day. David Biel -
Morgan Stanley - Analyst Okay, great. Operator Your next question
comes from the line of Steven Harper of Thomas Weisel Partners.
Please proceed. Steven Halper - Thomas Weisel Partners - Analyst
Yes, hi. On the integrated strategy that you're going to be rolling
out in February, is that going to be focused, is that sales
orientation, is that going to go to hospital CEOs, CIOs, pharmacy
directors, if you could just give us some color on who the
initiatives going to be focused at? Dave Schlotterbeck - Cardinal
Health, Inc. - CEO, Pharmaceutical, Medical Products Yes, Steven.
The decision makers involved here will be the senior executives of
the hospital. They will include the Chief Information Officers and
the Directors of Pharmacy. One of the things that we have focused
on is making this as easy an adoption as possible for the CIO
because they do have a pretty significant say in what gets
purchased as in terms of information related products, and our
whole strategy here has been to make this essentially effortless
for the CIO, so we're very optimistic about the reception that we
expect to see in the marketplace. Steven Halper - Thomas Weisel
Partners - Analyst Great. Thanks. Dave Schlotterbeck - Cardinal
Health, Inc. - CEO, Pharmaceutical, Medical Products Yes. Jeff
Henderson - Cardinal Health, Inc. - CFO Before we move on,
Operator, we'll take a few more questions. Think was one thing I
did want to clarify for everyone because it will probably save you
countless hours of pain trying to figure it out later and that is
that the tax gain that was reflected in our discontinued operations
related to PTS, and let me just give you a one minute background on
this. That particular income item was generated really due to the
fact that we have a difference between our tax basis for PTS which
is about 3.1 billion and our net book value which is 2 billion, and
that difference creates a deferred tax asset and the fact that we
treated PTS's discontinued operations really triggered the need to
recognize that asset and flow it through the income statement
within discontinued operations so that was a $425 million tax gain
that is reflected in discontinued ops. Now, what will actually
happen in the quarter that we close the sale, assuming we have
estimated net proceeds around 3.1 billion, a net book value of 2
billion, we'll recognize a gross gain of 1.1 billion, recognize a
tax expense of 0.4 billion which is effectively offsetting the
asset we just recognized for an after-tax gain of approximately 0.7
billion, so you could say cumulatively, if you include the gain we
took this quarter and the after-tax gain we expect to take in the
quarter that we close the sale, we'll www.streetevents.com Contact
Us 18 2007 Thomson Financial. Republished with permission. No part
of this publication may be reproduced or transmitted in any form or
by any means without the prior written consent of Thomson
Financial.
20. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call have recognized a
cumulative net book gain in '07 of 1.1 billion. And hopefully that
clears it up a little bit but I suspect we'll still have a few more
questions. With that, Operator? Maybe we'll take two more questions
and call it a day. Operator Your next question comes from the line
of [Charles Bardy] of Citigroup. Please proceed. Charles Bardy -
Citigroup - Analyst Hi, thanks. On the Pyxis demand growth, can you
characterize how much was new customers versus customers upgrading
to the 3,500 and what was domestic versus -- are you seeing any
successes on the international front with the Pyxis machine? Dave
Schlotterbeck - Cardinal Health, Inc. - CEO, Pharmaceutical,
Medical Products Yes. Well, since the market is pretty well
penetrated, the majority of the Pyxis growth in the last quarter or
bookings in the last quarter really comes from existing customers
that are upgrading to new product. Internationally, we are
beginning to see significant growth by Pyxis and are very
optimistic about where that will take us. Charles Bardy - Citigroup
- Analyst Can you venture any estimates on size in terms of how big
that European market may be in relation to the U.S. market and
whether the competition there is as difficult and if it's as
penetrated as the U.S. market? Dave Schlotterbeck - Cardinal
Health, Inc. - CEO, Pharmaceutical, Medical Products Well, it is
under penetrated at the moment and that means that it's a
significant opportunity and we are using the existing
infrastructure to begin that penetration. We do find that there are
different needs in European hospitals than in U.S. hospitals and so
we do have to tailor products to meet the needs of the customer.
The overall market, I would put at several 100 million dollars that
is when it is fully matured, but at this point in time, it's a long
way from being mature. Kerry Clark - Cardinal Health, Inc. -
President, CEO And I think the only thing that I would add to that
is the Pyxis supply stations may very well be over developed, may
over develop in Europe relative to the MedStations compared to --
there's a lot of consumer interest, customer interest in the supply
station in Europe as well, and so I think that will become a
significant part of our offering in that market. Charles Bardy -
Citigroup - Analyst Are you suggesting the supply stations will
help pull in the Pyxis station or vice versa? Kerry Clark -
Cardinal Health, Inc. - President, CEO I think what we're seeing,
that hospital customers have a lot of interest in controlling their
Medical Products cost in Europe and I think the U.S. is slightly
more advanced on the safety aspects in medication in hospital than
their European counterparts are. www.streetevents.com Contact Us 19
2007 Thomson Financial. Republished with permission. No part of
this publication may be reproduced or transmitted in any form or by
any means without the prior written consent of Thomson
Financial.
21. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call Charles Bardy -
Citigroup - Analyst Thank you. Jeff Henderson - Cardinal Health,
Inc. - CFO Okay, Operator, last question, please? Operator Your
final question comes from the line of Robert Willoughby of Banc of
America Securities. Please proceed. Robert Willoughby - Banc of
America Securities - Analyst Hi, Kerry or Jeff, with the businesses
rebounding along the lines that you've guided, maybe slightly ahead
from a profit standpoint, and the check coming in from PTS here in
a couple quarters, why not do the big buyback today rather than two
quarters down when the stock may be higher? Jeff Henderson -
Cardinal Health, Inc. - CFO Bob, it's Jeff. I don't want to comment
on the specific timing of the buyback. Obviously, the timing will
depend on market conditions and other factors and we'll continue to
assess those as time goes on. Robert Willoughby - Banc of America
Securities - Analyst Thanks very much. Operator And I'll now turn
it back to the speakers for closing remarks. Kerry Clark - Cardinal
Health, Inc. - President, CEO I just want to say thanks everybody
for joining us today and thank you for your questions. As I said
earlier on, we're feeling very positive about the progress we've
made in this last quarter and are feeling very good about the
second half. So thank you very much. Jeff Henderson - Cardinal
Health, Inc. - CFO Thank you. Operator Ladies and gentlemen, thank
you for your participation in today's conference. This concludes
the presentation. You may now disconnect. Have a good day.
www.streetevents.com Contact Us 20 2007 Thomson Financial.
Republished with permission. No part of this publication may be
reproduced or transmitted in any form or by any means without the
prior written consent of Thomson Financial.
22. FINAL TRANSCRIPT Jan. 25. 2007 / 11:00AM, CAH - Q2 2007
Cardinal Health, Inc. Earnings Conference Call DISCLAIMER Thomson
Financial reserves the right to make changes to documents, content,
or other information on this web site without obligation to notify
any person of such changes. In the conference calls upon which
Event Transcripts are based, companies may make projections or
other forward-looking statements regarding a variety of items. Such
forward-looking statements are based upon current expectations and
involve risks and uncertainties. Actual results may differ
materially from those stated in any forward-looking statement based
on a number of important factors and risks, which are more
specifically identified in the companies' most recent SEC filings.
Although the companies may indicate and believe that the
assumptions underlying the forward-looking statements are
reasonable, any of the assumptions could prove inaccurate or
incorrect and, therefore, there can be no assurance that the
results contemplated in the forward-looking statements will be
realized. THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A
TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL
AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,
THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE
REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES
THOMSON FINANCIAL OR THE APPLICABLE COMPANY ASSUME ANY
RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED
UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT
TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S
CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS
BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS. 2007, Thomson
Financial. All Rights Reserved. 1453165-2007-01-26T10:52:24.060
www.streetevents.com Contact Us 21 2007 Thomson Financial.
Republished with permission. No part of this publication may be
reproduced or transmitted in any form or by any means without the
prior written consent of Thomson Financial.